PMID- 16700779
OWN - NLM
STAT- MEDLINE
DCOM- 20061024
LR  - 20181201
IS  - 0011-9059 (Print)
IS  - 0011-9059 (Linking)
VI  - 45
IP  - 5
DP  - 2006 May
TI  - Current modalities and new advances in the treatment of basal cell carcinoma.
PG  - 489-98
AB  - Basal cell carcinoma (BCC) is one of the most common cancers. Surgical 
      extirpation is currently the standard of care for BCC, which is associated with 
      several advantages and disadvantages. Procedures such as surgical excision used 
      to treat superficial BCC (sBCC) and nodular BCC (nBCC) may have high 5-year 
      recurrence rates if tumors are not completely excised. Curettage with 
      electrodesiccation is a common method for treating primary BCC. However, multiple 
      cycles are recommended and the procedure can have unsatisfactory cosmetic results 
      (e.g. scarring and hypopigmentation). Mohs micrographic surgery has a low rate of 
      disease recurrence but is a specialized procedure usually limited to specific 
      indications (e.g. high-risk tumors). Cryosurgery and photodynamic therapy require 
      multiple cycles and are associated with variable cosmetic outcomes and recurrence 
      rates. As with any procedure, potential risks and patient quality-of-life issues 
      need to be considered. In addition, substantial patient and healthcare provider 
      inconvenience limit the practical utility of some modalities. Pharmacologic 
      interventions provide another treatment option as adjunctive or monotherapy. 
      Investigations of imiquimod, a novel immune response modifier, have indicated 
      that this topical, noninvasive agent is safe and well tolerated and may be 
      efficacious in the treatment of BCC. This review will highlight the role of 
      standard treatment modalities and introduce new advances in the treatment of BCC.
FAU - Ceilley, Roger I
AU  - Ceilley RI
AD  - Department of Dermatology, University of Iowa School of Medicine, Iowa City, IA, 
      USA. Ricakb@aol.com
FAU - Del Rosso, James Q
AU  - Del Rosso JQ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Aminoquinolines)
RN  - 0 (Antineoplastic Agents)
RN  - P1QW714R7M (Imiquimod)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aminoquinolines/administration & dosage/therapeutic use
MH  - Antineoplastic Agents/administration & dosage/therapeutic use
MH  - Carcinoma, Basal Cell/pathology/*therapy
MH  - Cryosurgery
MH  - Curettage
MH  - Electrosurgery
MH  - Humans
MH  - Imiquimod
MH  - Mohs Surgery
MH  - Neoplasm Recurrence, Local/pathology/*therapy
MH  - Photochemotherapy
MH  - Skin Neoplasms/pathology/*therapy
RF  - 58
EDAT- 2006/05/17 09:00
MHDA- 2006/10/25 09:00
CRDT- 2006/05/17 09:00
PHST- 2006/05/17 09:00 [pubmed]
PHST- 2006/10/25 09:00 [medline]
PHST- 2006/05/17 09:00 [entrez]
AID - IJD2673 [pii]
AID - 10.1111/j.1365-4632.2006.02673.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2006 May;45(5):489-98. doi: 10.1111/j.1365-4632.2006.02673.x.